Conditional DOE loan could advance domestic Mo-99 supply
The conditional commitment would support completion of Chrysalis, a Janesville, WI, facility designed to establish domestic commercial production of molybdenum-99.
SHINE Technologies has received a conditional commitment for a loan of up to $263M from the U.S. Department of Energy to support construction of Chrysalis, a medical isotope production facility in Janesville, WI.
The financing would support completion of a high-volume facility intended to establish the first domestic commercial supply of molybdenum-99, according to SHINE.
Mo-99 is used in more than 40,000 diagnostic procedures daily to diagnose heart disease, cancer, and other conditions, according to the company and DOE. The U.S. currently relies on imports from Europe, South Africa, and Australia for supply.
Because Mo-99 decays at about 1% per hour, SHINE said roughly 1/3 of its volume and value is lost during cross-continental transport. The company said domestic production would reduce logistics-related supply vulnerability.
Chrysalis uses SHINE’s fusion technology platform and a liquid uranium target to produce Mo-99. The company said the facility is also designed to produce iodine-131, xenon-133, and other medical isotopes.
Once fully operational, Chrysalis is expected to be the largest medical isotope production facility in the world, according to SHINE. DOE said the project would create a reliable and secure supply of medical isotopes made with fusion and fission technology.
The loan has not been finalized. DOE said the conditional commitment depends on SHINE satisfying technical, legal, environmental, and financial conditions before closing.
Sources
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
More from this section
Pathology support broadens MedDream viewer scope
Version 8.9.0 is scheduled for June 2026 through aycan and will add support for pathology workflows and saving reconstructed MPR viewports as new study series.
DOSIsoft unit gives PLANET a theranostics focus
DOSIsoft Theranostics will operate within the DOSIsoft group, with its own partnerships and investment strategy centered on PLANET software.
Vault-ready proton system headed to Tam Anh
Mevion said the S250-FIT installation would be Vietnam’s first proton therapy system, with operation expected as early as late 2027 at Tam Anh’s Phu My Hung facility.
I-MED sale gives Jardines 215-clinic radiology network
Jardine Matheson will acquire 100% of I-MED Radiology Network in a deal valued at A$3.4B, including I-MED’s minority stake in Harrison.ai.
Expected Russell addition puts Hyperfine in small-cap benchmarks
FTSE Russell’s preliminary June reconstitution list includes Hyperfine, with index changes set to take effect after U.S. markets close on June 26.
Curium approach puts Lantheus deal value near $7B
Lantheus is weighing a potential sale after an approach from Curium Pharma, while company filings show recent Pylarify pressure and pending PET regulatory milestones.
Niowave Lansing site to scale Ac-225 supply by 2028
The Lansing, MI, site will house superconducting linear accelerators and radiochemistry systems to support scalable actinium-225 production, with completion expected in 2028.
30-year GE-UW tie expands into CT and theranostics research
The collaboration will focus on CT and molecular imaging technologies for cardiology, oncology, and theranostics workflows at UW Medicine Radiology facilities in Seattle.
Recall issues and isotope shortages weigh on Radnostix Q1 revenue
The radioisotope-focused company reported $2.38M in Q1 revenue, citing recall impacts, isotope shortages, and Cobalt-60 hot cell downtime.
Ephemeral to build AI data platform for Plus CNS oncology programs
The companies will develop an AI platform to integrate therapeutic, diagnostic, and bioinformatics data across Plus Therapeutics’ CNS oncology programs.
Fujifilm balloon-free EBUS scope targets pulmonary setup time
The EB-710US Ultrasound Bronchoscope is designed for pulmonary procedures and will be demonstrated at the American Thoracic Society Conference.
ACIST Pro brings contrast tracking upgrade to U.S. cath labs
The Bracco company received U.S. clearance and launched ACIST Pro, a variable-rate contrast management system for image-guided cardiovascular procedures.